Multimodal Therapy Impact on Pancreatic Cancer Survival

NCT06938906 | Active Not Recruiting

• 1 other identifier: NCKUH-11405009
• Study Type: observational
• Target: 405
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this retrospective cohort study is to analyze change of treatment strategies affect the survival outcomes in patients of pancreatic cancer who received curative-intent treatment. The main question it aims to answer is: Hypothesis: Change of treatment strategies involving increased utility of neoadjuvant chemotherapy and aggressive surgical approaches of extended pancreatectomy improved the overall and progression free survival in the patients with pancreatic cancer. Participants received curative treatment for pancreatic cancer.

Conditions

Pancreatic Cancer; Neoadjuvant Chemotherapy; Pancreatectomy

Keywords

pancreatic cancer; neoadjuvant chemotherapy; extended pancreatectomy; multimodal therapy; paradigm shift; survival outcomes

Outcome Measures

Primary Outcomes (1)

• Overall survival and Progression-free survival

  Overall survival was calculated from the first treatment day of the disease to the day of mortality. Progression-free survival was calculated from the first treatment day of the disease to the day of proression or recurrece of pancreatic cancer.

  From enrollment to two years after the end of treatment

Study Arms (2)

Group A

The patient of pancreatic cancer, who began to have treatment in the period between 2011 to 2017.

Group B

The patient of pancreatic cancer, who began to have treatment in the period between 2018 to 2022.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with pancreatic cancer who lived in southern Taiwan.

You may qualify if:

• Pancreatic adenocarcinoma
• Received curative surgery

You may not qualify if:

• Other subtypes of pancreatic cancer including acinar cell carcinoma, mucinous carcinoma, undifferentiated carcinoma and intraductal papillary mucinous neoplasm with associated adenocarcinoma
• Cases with palliative or R2 resection were also excluded from the analysis.

Sponsors & Collaborators

• National Cheng Kung University: lead

Study Sites (1)

National Cheng Kung University Hospital

Tainan, 704, Taiwan

Location

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases

Study Officials

• Yan-Shen Shan, MD., PhD.

  Department of Surgery, National Cheng Kung University Hospital

  STUDY CHAIR

• Ting-Kai Liao, MD.

  National Cheng-Kung University Hospital

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator, Director of Specialized Ward for Division of General Surgery, Department of Surgery

Study Record Dates

• First Submitted: April 14, 2025
• First Posted: April 22, 2025
• Study Start: January 3, 2011
• Primary Completion: April 30, 2025
• Study Completion: April 30, 2025
• Last Updated: April 24, 2025

Record last verified: 2025-04

Locations

TW (1)